Device profile of Nerivio for the acute and preventive treatment of episodic or chronic migraine in patients 12 years and older

ABSTRACT

Introduction

Migraine is a prevalent, inherited and disabling brain disease with multiple symptoms and a variety of treatment options. Nerivio, utilizing remote electrical neuromodulation (REN) a wearable device, offers users good efficacy, tolerability and safety. It is user-friendly, affordable, non-addictive and cleared by the FDA and the European Conformity.

Areas covered

The device structure, mechanism of action, indications for use, application instructions, efficacy, adverse events, tolerability, safety, patient satisfaction, associated application and the research highlights are discussed herein.

Expert opinion

The device works well for most people living with migraine, often without concomitant medication, is tolerable, safe and causes minimal and mild adverse effects. It expands our migraine treatment options and improves patient adherence to treatment. Nerivio is easy-to-use and can be worn at any time of the day; it provides a non-pharmacologic option for the optimization of migraine treatment without significant adverse events.

KEYWORDS:

• Nerivio
• migraine
• migraine acute treatment
• migraine preventive treatment
• menstrual migraine
• triptans
• NSAIDs
• adolescent migraine treatment

Article highlights

• Nerivio is a REN device for acute and/or preventive treatment of episodic and chronic migraine with or without aura in adolescents and adults.

• FDA clearance and CE approval have been granted to Nerivio for migraine treatment.

• Neurostimulation signals are non-painful as ensured by an individualized ability for each patient to adjust their own intensity of treatment.

• The device is wireless and wearable on either upper arm, secured in place by an armband and applicable at anytime, anywhere.

• Nerivio has excellent efficacy, tolerability, and patient satisfaction, as well as very few non-serious adverse effects.

• Nerivio is non-inferior to usual pharmacological migraine treatments.

• The device can be used instead of or along with over-the-counter or migraine specific medications.

• This device is only available by prescription and is shipped to the patient’s house by a specialized pharmacy.

Declaration of interest

Alan M. Rapoport M.D. serves as an advisor for AbbVie, Biohaven, Cala Health, Collegium Pharma, Satsuma, Teva Pharmaceutical Industries, Theranica and Xoc; he is on the Speakers Bureau of AbbVie, Amgen, Biohaven, Collegium, Pfizer, Impel, Lundbeck and Teva Pharmaceutical Industries. He is Editor-in-Chief of Neurology Reviews. He is on the Editorial Board of CNS Drugs. He owns shares of 30 Madison and Schedule 1 Therapeutics. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

Reviewers disclosure

Peer reviewers on this manuscript have no relevant financial relationships or otherwise to disclose.

Additional information

Funding

This paper was not funded.